Several unmet needs have been identified in allergic rhinitis: identification of the time of
onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification …

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several
factors, including age, prominent symptoms, symptom severity, control of AR, patient …

In patients with cystic fibrosis (CF), the lung is a remarkable ecological niche in which the
microbiome is subjected to important selective pressures. An inexorable colonization by …

BACKGROUND: A light-porous-particle, dry-powder formulation of tobramycin was
developed, using PulmoSphere® technology, to improve airway delivery efficiency …

Rationale: Elexacaftor–tezacaftor–ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane
conductance regulator) modulator combination, developed for patients with CF with at least …

Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

ABSTRACT The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-
ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic …

Background Idiopathic pulmonary hemosiderosis (IPH) is a rare cause of alveolar
hemorrhage in children and its pathophysiology remains obscure. Classically, diagnosis is …

Rationale: Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance
regulator) modulator combination recently approved for patients with cystic fibrosis (CF) …

Objective To investigate the short-term adverse events and effectiveness of
lumacaftor/ivacaftor combination treatment in adults with cystic fibrosis (CF) and severe lung …